☰

Eric N. Nadler, Ph.D. - Publications

Affiliations: 
2007 Alliant International University, San Francisco Bay 
Area:
Clinical Psychology, Physiological Psychology, Rehabilitation and Therapy
Tree Info Grants Similar researchers Related pubs Distance to... Nearest Nobel PubMed Report error

0/32 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
Low-probability matches (unlikely to be authored by this person)
2023 Le X, Nadler E, Costa DB, Heymach JV. Correction to: EGFR Tyrosine Kinase Inhibitors for the Treatment of Metastatic Non‑Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Podcast. Targeted Oncology. PMID 38070005 DOI: 10.1007/s11523-023-01020-1  0.01
2023 Le X, Nadler E, Costa DB, Heymach JV. Correction to: EGFR Tyrosine Kinase Inhibitors for the Treatment of Metastatic Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Podcast. Targeted Oncology. PMID 37891443 DOI: 10.1007/s11523-023-01010-3  0.01
2023 Le X, Nadler E, Costa DB, Heymach JV. EGFR Tyrosine Kinase Inhibitors for the Treatment of Metastatic Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Podcast. Targeted Oncology. PMID 37792237 DOI: 10.1007/s11523-023-00994-2  0.01
2023 Nadler E, Vasudevan A, Wentworth C, Robert N, Penrod JR, Fiore J, Vo L. Real-world relationship of early endpoints to survival endpoints in patients with resectable non-small-cell lung cancer. Future Oncology (London, England). PMID 37665271 DOI: 10.2217/fon-2023-0170  0.01
2023 Black CM, Ramakrishnan K, Nadler E, Tseng WY, Wentworth C, Murphy J, Fulcher N, Wang L, Alexander M, Patton G. Real-world study of patients with locally advanced HNSCC in the community oncology setting. Frontiers in Oncology. 13: 1155893. PMID 37664029 DOI: 10.3389/fonc.2023.1155893  0.01
2022 Pokras S, Tseng WY, Espirito JL, Beeks A, Culver K, Nadler E. Treatment patterns and outcomes in metastatic synovial sarcoma: a real-world study in the US oncology network. Future Oncology (London, England). PMID 36018238 DOI: 10.2217/fon-2022-0477  0.01
2022 Nadler E, Vasudevan A, Wang Y, Ogale S. Real-world patterns of biomarker testing and targeted therapy in de novo metastatic non-small cell lung cancer patients in the US oncology network. Cancer Treatment and Research Communications. 31: 100522. PMID 35189530 DOI: 10.1016/j.ctarc.2022.100522  0.01
2021 Taylor MH, Betts CB, Maloney L, Nadler E, Algazi A, Guarino MJ, Nemunaitis J, Jimeno A, Patel P, Munugalavadla V, Tao L, Adkins D, Goldschmidt JH, Cohen EEW, Coussens LM. Safety and Efficacy of Pembrolizumab in Combination With Acalabrutinib in Advanced Head and Neck Squamous Cell Carcinoma: Phase 2 Proof-of-Concept Study. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 34862248 DOI: 10.1158/1078-0432.CCR-21-2547  0.01
2020 Nadler E, Arondekar B, Aguilar KM, Zhou J, Chang J, Zhang X, Pawar V. Treatment patterns and clinical outcomes in patients with advanced non-small cell lung cancer initiating first-line treatment in the US community oncology setting: a real-world retrospective observational study. Journal of Cancer Research and Clinical Oncology. PMID 33263865 DOI: 10.1007/s00432-020-03414-4  0.01
2020 Nadler E, Espirito JL, Pavilack M, Baidoo B, Fernandes A. Real-world disease burden and outcomes of brain metastases in mutation-positive non-small-cell lung cancer. Future Oncology (London, England). 16: 1575-1584. PMID 32495656 DOI: 10.2217/fon-2020-0280  0.01
2020 Nadler E, Aguilar K, Wentworth C, Boyd M, Amirian ES, Barker S, French P, Wilson T, Hess LM. Treatment Patterns and Healthcare Resource Utilization among Patients with Advanced or Metastatic Soft Tissue Sarcoma in US Community Practices. Sarcoma. 2020: 1765319. PMID 32256184 DOI: 10.1155/2020/1765319  0.01
2020 Nadler E, Pavilack M, Espirito JL, Clark J, Fernandes A. Observational Study of Treatment Patterns in Patients with Epidermal Growth Factor Receptor (EGFR) Mutation-Positive Non-Small Cell Lung Cancer After First-Line EGFR-Tyrosine Kinase Inhibitors. Advances in Therapy. PMID 31955357 DOI: 10.1007/s12325-020-01221-4  0.01
2018 Nadler E, Joo S, Boyd M, Black-Shinn J, Chirovsky D. Treatment patterns and outcomes among patients with recurrent/metastatic squamous cell carcinoma of the head and neck. Future Oncology (London, England). PMID 30511880 DOI: 10.2217/fon-2018-0572  0.01
2018 Nadler E, Espirito JL, Pavilack M, Boyd M, Vergara-Silva A, Fernandes A. Treatment Patterns and Clinical Outcomes Among Metastatic Non-Small-Cell Lung Cancer Patients Treated in the Community Practice Setting. Clinical Lung Cancer. PMID 29576407 DOI: 10.1016/j.cllc.2018.02.002  0.01
2017 Ersek JL, Nadler E, Freeman-Daily J, Mazharuddin S, Kim ES. Clinical Pathways and the Patient Perspective in the Pursuit of Value-Based Oncology Care. American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Meeting. 37: 597-606. PMID 28561657 DOI: 10.14694/EDBK_174794  0.01
2017 Calabrese C, Mejia B, McInnis CA, France M, Nadler E, Raslear TG. Time of day effects on railroad roadway worker injury risk. Journal of Safety Research. 61: 53-64. PMID 28454871 DOI: 10.1016/j.jsr.2017.02.007  0.01
2014 Chen C, Borker R, Ewing J, Tseng WY, Hackshaw MD, Saravanan S, Dhanda R, Nadler E. Epidemiology, treatment patterns, and outcomes of metastatic soft tissue sarcoma in a community-based oncology network. Sarcoma. 2014: 145764. PMID 24683310 DOI: 10.1155/2014/145764  0.01
2012 Ubel PA, Berry SR, Nadler E, Bell CM, Kozminski MA, Palmer JA, Evans WK, Strevel EL, Neumann PJ. In a survey, marked inconsistency in how oncologists judged value of high-cost cancer drugs in relation to gains in survival. Health Affairs (Project Hope). 31: 709-17. PMID 22492887 DOI: 10.1377/hlthaff.2011.0251  0.01
2012 Nadler E, Forsyth M, Satram-Hoang S, Reyes C. Costs and clinical outcomes among patients with second-line non-small cell lung cancer in the outpatient community setting. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 7: 212-8. PMID 22124474 DOI: 10.1097/Jto.0B013E3182307F33  0.01
2011 Nadler E, Yu E, Ravelo A, Sing A, Forsyth M, Gruschkus S. Bevacizumab treatment to progression after chemotherapy: outcomes from a U.S. community practice network. The Oncologist. 16: 486-96. PMID 21441299 DOI: 10.1634/theoncologist.2010-0287  0.01
2011 McCormack LA, Treiman K, Rupert D, Williams-Piehota P, Nadler E, Arora NK, Lawrence W, Street RL. Measuring patient-centered communication in cancer care: a literature review and the development of a systematic approach. Social Science & Medicine (1982). 72: 1085-95. PMID 21376443 DOI: 10.1016/J.Socscimed.2011.01.020  0.01
2011 Reddy GK, Nadler E, Jain VK. Denosumab (AMG 162), a Fully Human Monoclonal Antibody Against RANK Ligand Activity. Supportive Cancer Therapy. 3: 14-5. PMID 18632429 DOI: 10.1016/s1543-2912(13)60114-9  0.01
2011 Tyagi P, Jain VK, Nadler E. Therapeutic use of the cannabinoid receptor antagonist rimonabant in weight loss and smoking cessation. Supportive Cancer Therapy. 3: 11-3. PMID 18632428 DOI: 10.1016/s1543-2912(13)60113-7  0.01
2011 Redd GK, Tyagi P, Nadler E, Jain VK. Highlights from: The 9th International Congress on Hematologic Malignancies, Whistler, BC, Canada. Supportive Cancer Therapy. 3: 7-10. PMID 18632427 DOI: 10.1016/s1543-2912(13)60112-5  0.01
2011 Reddy K, Jain VK, Nadler E. Role of psychostimulants in the management of cancer-related fatigue in patients with advanced cancer. Supportive Cancer Therapy. 2: 212-4. PMID 18628175 DOI: 10.1016/s1543-2912(13)60139-3  0.01
2011 Reddy GK, Jain VK, Nadler E, Crawford J. Highlights from: The 41st Annual Meeting of the American Society of Clinical Oncology; Orlando, FL. Supportive Cancer Therapy. 2: 203-7. PMID 18628173 DOI: 10.1016/s1543-2912(13)60137-x  0.01
2010 Berry SR, Bell CM, Ubel PA, Evans WK, Nadler E, Strevel EL, Neumann PJ. Continental Divide? The attitudes of US and Canadian oncologists on the costs, cost-effectiveness, and health policies associated with new cancer drugs. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 28: 4149-53. PMID 20697077 DOI: 10.1200/JCO.2010.29.1625  0.01
2010 Neumann PJ, Palmer JA, Nadler E, Fang C, Ubel P. Cancer therapy costs influence treatment: A national survey of oncologists Health Affairs. 29: 196-202. PMID 20048377 DOI: 10.1377/hlthaff.2009.0077  0.01
2009 Rosenberger PH, Ickovics JR, Epel E, Nadler E, Jokl P, Fulkerson JP, Tillie JM, Dhabhar FS. Surgical stress-induced immune cell redistribution profiles predict short-term and long-term postsurgical recovery. A prospective study. The Journal of Bone and Joint Surgery. American Volume. 91: 2783-94. PMID 19952239 DOI: 10.2106/Jbjs.H.00989  0.01
2006 Nadler E, Eckert B, Neumann PJ. Do oncologists believe new cancer drugs offer good value? The Oncologist. 11: 90-5. PMID 16476830 DOI: 10.1634/theoncologist.11-2-90  0.01
2005 Reddy GK, Nadler E, Jain VK. Preoperative chemoradiation therapy shows improved clinical benefit in patients with rectal cancer. Clinical Colorectal Cancer. 5: 163-5. PMID 16197618 DOI: 10.1016/s1533-0028(11)70179-7  0.01
2002 Pilcher JJ, Nadler E, Busch C. Effects of hot and cold temperature exposure on performance: a meta-analytic review. Ergonomics. 45: 682-98. PMID 12437852 DOI: 10.1080/00140130210158419  0.01
Hide low-probability matches.